NTR1 Antibody

What is NTR1 and what is its biological function?

NTR1 (also known as NTSR1, NT-R-1, NTRH, NTRR) is a G protein-coupled receptor that serves as a high-affinity receptor for the tridecapeptide neurotensin. It mediates multiple physiological functions including hypotension, hyperglycemia, hypothermia, antinociception, and regulation of intestinal motility and secretion . NTR1 can couple to various G proteins including Gq, Gi/o, or Gs, initiating different intracellular signaling cascades . It is primarily a multi-pass membrane protein that requires palmitoylation for localization at caveolin-1-enriched membrane rafts .

What types of NTR1 antibodies are available for research?

Researchers can utilize both polyclonal and monoclonal antibodies against NTR1:

• Polyclonal antibodies: These detect endogenous levels of NTR1 protein and are typically produced in rabbits against specific epitopes of human NTR1 .

• Monoclonal antibodies: Mouse-derived monoclonal antibodies that recognize specific regions of human NTR1, such as amino acids 181-230 .

• Anti-Neurotensin Receptor 1 (extracellular) Antibody: Specifically targets the extracellular domain, corresponding to amino acid residues 209-224 of human NTSR1 within the 2nd extracellular loop .

What is the molecular size of NTR1 protein detected by antibodies?

The molecular weight of NTR1 protein detected by antibodies varies slightly depending on the source and detection method:

• In Western blot analysis, NTR1 is typically observed at approximately 65 kDa according to some antibody specifications .

• Other antibodies may detect NTR1 at approximately 46 kDa, likely representing different glycosylation states or splice variants .

What species reactivity is available for NTR1 antibodies?

Most commercial NTR1 antibodies demonstrate reactivity against human and mouse NTR1 . The cross-reactivity enables comparative studies across species. Some specialized antibodies have been validated for use in rat models as well, particularly for neurological studies examining NTR1 expression in brain tissue .

What are the validated applications for NTR1 antibodies?

NTR1 antibodies have been validated for multiple experimental applications:

These applications allow for comprehensive characterization of NTR1 expression across diverse experimental systems .

What are the recommended protocols for using NTR1 antibodies in immunohistochemistry?

For optimal immunohistochemical detection of NTR1:

• Use freshly prepared 4% paraformaldehyde-fixed tissues or FFPE sections (4-6 μm thickness).

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Block with 5-10% normal serum from the same species as the secondary antibody.

• Apply primary NTR1 antibody at 1:100 dilution and incubate overnight at 4°C.

• Use appropriate detection systems - DAB produces brown staining specific for epithelium-derived malignant cells when counterstained with hematoxylin .

• Include positive control tissues (breast cancer, colon cancer samples) and negative controls (primary antibody omission).

Research has shown this approach effectively distinguishes NTR1 expression patterns in normal versus malignant tissues, with significantly higher expression observable in tumor tissues (71.0% positive) compared to adjacent normal tissues (13.3% positive) .

How should NTR1 antibodies be optimized for Western blot analysis?

For successful Western blot detection of NTR1:

• Prepare cell/tissue lysates in RIPA buffer supplemented with protease inhibitors.

• Load 20-50 μg protein per lane for cell lines expressing endogenous NTR1.

• Use 8-10% SDS-PAGE gels to achieve optimal separation of the 46-65 kDa protein.

• Transfer to PVDF membranes (preferred over nitrocellulose for this receptor).

• Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Apply anti-NTR1 antibody at 1:200-1:500 dilution for primary detection .

• Include appropriate positive controls such as human colon cancer HT-29, lung small cell carcinoma NCI-H526, or breast adenocarcinoma MDA-MB-468 cell lysates .

• Validate specificity using blocking peptides when available.

This protocol has been successfully used to detect NTR1 in multiple cancer cell lines as demonstrated in published studies .

What controls should be used when working with NTR1 antibodies?

To ensure experimental validity when using NTR1 antibodies:

• Positive controls:

  • Cell lines: HT-29 (colon cancer), NCI-H526 (lung cancer), MDA-MB-468 (breast cancer), MCF-7 (breast cancer), and HL-60 (promyelocytic leukemia) cells .

  • Tissues: Breast cancer sections, colon cancer samples, and specific brain regions for neurological studies.

• Negative controls:

  • Primary antibody omission.

  • Antibody pre-incubation with the immunizing peptide (blocking peptide) .

  • Non-expressing tissues or cell lines for comparison.

• Validation controls:

  • Peptide competition assays to confirm specificity.

  • siRNA knockdown to confirm specificity in cell-based assays.

  • Comparison of staining patterns using antibodies targeting different epitopes.

How does NTR1 expression correlate with cancer progression and prognosis?

NTR1 expression has emerged as a significant factor in cancer progression across multiple tumor types:

In gastric cancer specifically, 71.0% of tumors exhibit positive NTR1 staining compared to only 13.3% of adjacent normal gastric mucosa, with NTR1 expression positively correlated with pathological grade, T stage, N stage, and TNM stage (p<0.05) . Univariate analysis has established NTR1 expression as a significant factor related to postoperative survival, suggesting its potential as both a prognostic marker and therapeutic target .

What is the relationship between NTR1 and β-catenin signaling?

The interaction between NTR1 and β-catenin signaling has been documented in research on gastric cancer progression:

• NTR1 appears to modulate β-catenin signaling, potentially through indirect mechanisms involving G-protein coupled pathways.

• Studies suggest a correlation between elevated NTR1 expression and enhanced β-catenin nuclear localization in gastric cancer samples.

• This interaction may participate in tumor progression mechanisms, contributing to increased invasiveness and metastatic potential .

• The relationship between these pathways could provide mechanistic insight into how NTR1 promotes aggressive cancer phenotypes.

Further research is needed to fully elucidate the molecular interactions between NTR1 and the β-catenin pathway, as this connection may represent a promising target for therapeutic intervention .

How can NTR1 antibodies be used to explore receptor localization and trafficking?

Advanced microscopy techniques using NTR1 antibodies can reveal important insights about receptor dynamics:

• Subcellular localization studies:

  • Immunofluorescence analysis using extracellular domain-specific NTR1 antibodies has demonstrated membrane localization in live intact cells, including MCF-7 breast cancer cells .

  • Confocal microscopy with NTR1 antibodies reveals receptor clustering in membrane rafts, dependent on palmitoylation .

• Trafficking visualization:

  • Time-course internalization assays using extracellular NTR1 antibodies can track receptor endocytosis following neurotensin stimulation.

  • Dual-labeling strategies with endosomal markers help map the intracellular fate of NTR1.

• Co-localization with signaling partners:

  • NTR1 antibodies have been used in co-immunostaining experiments, such as with ChAT (choline acetyltransferase) in rat brain sections, revealing NTR1 expression in cholinergic neurons of the diagonal band region .

These approaches provide valuable information about the spatial regulation of NTR1 and its integration with cellular signaling networks.

What experimental designs are optimal for studying NTR1 in different cancer models?

To effectively investigate NTR1 in cancer research:

• Cell line models:

  • Selection of appropriate NTR1-expressing cell lines (HT-29, NCI-H526, MDA-MB-468, MCF-7) for in vitro studies .

  • Stable knockdown/overexpression systems to directly assess NTR1 contribution to proliferation, migration, and invasion.

  • Comparison between primary cell cultures and established lines to account for potential artifacts.

• Animal models:

  • Xenograft models using NTR1-manipulated cell lines to evaluate tumor growth and metastasis in vivo.

  • Genetically engineered mouse models with tissue-specific NTR1 alterations.

  • Patient-derived xenografts to maintain tumor heterogeneity.

• Patient samples:

  • Stratification based on NTR1 expression levels using standardized IHC scoring systems.

  • Correlation of NTR1 expression with clinical parameters and outcomes.

  • Integration with genomic and proteomic data to identify key co-factors.

• Functional assays:

  • Receptor function assessment using receptor internalization, calcium mobilization, and MAPK activation.

  • Inhibitor studies using NTR1 antagonists to evaluate therapeutic potential.

How to address inconsistent staining patterns with NTR1 antibodies?

When encountering variable staining results:

• Optimize fixation conditions: Extended fixation may mask the NTR1 epitope. Compare 4% PFA for 10-30 minutes versus overnight fixation.

• Evaluate epitope accessibility: Different antibodies target distinct domains - extracellular domain antibodies may work better for membrane staining in non-permeabilized cells .

• Adjust antigen retrieval: Compare heat-induced epitope retrieval using citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0).

• Titrate antibody concentration: Perform dilution series between 1:20 to 1:300 to determine optimal signal-to-noise ratio .

• Compare detection systems: Fluorescent secondary antibodies may provide better resolution of membrane localization than chromogenic methods.

• Validate with multiple antibodies: Use antibodies targeting different epitopes to confirm staining patterns.

What might cause variability in NTR1 detection across different tissue samples?

Several factors can influence NTR1 detection in tissues:

• Tissue-specific expression patterns: NTR1 exhibits differential expression across tissues, with higher levels in certain cancers and lower levels in normal tissues .

• Receptor regulation: NTR1 expression can be dynamically regulated by hormones, growth factors, and disease states.

• Technical variations: Pre-analytical variables including time to fixation, fixative type, and processing methods affect epitope preservation.

• Cellular heterogeneity: Within tumors, NTR1 expression may vary by region, with potentially higher expression at infiltrating margins .

• Receptor internalization: Ligand-induced receptor internalization can alter the detectable pool of NTR1 at the cell surface.

Understanding these variables helps interpret expression data more accurately and design appropriate experimental controls.

How to interpret contradictory results between different detection methods?

When different techniques yield inconsistent NTR1 results:

• Consider method-specific limitations:

  • Western blot detects denatured protein and may miss conformational epitopes.

  • IHC preserves tissue architecture but may be affected by cross-reactivity.

  • Flow cytometry examines only surface expression in intact cells.

• Evaluate antibody characteristics:

  • Different antibodies target distinct epitopes that may be differentially accessible in various applications.

  • Polyclonal antibodies provide higher sensitivity but potentially lower specificity than monoclonals .

• Validate with orthogonal approaches:

  • Complement protein detection with mRNA analysis (RT-PCR, RNA-seq).

  • Use functional assays (receptor activation, signaling) to confirm biological relevance.

  • Employ genetic manipulation (siRNA, CRISPR) to confirm specificity.

• Consider biological variables:

  • Cell confluence, culture conditions, and passage number can affect NTR1 expression.

  • Receptor trafficking dynamics may lead to different subcellular distributions.

What considerations are important when quantifying NTR1 expression levels?

For accurate quantification of NTR1:

• Standardized scoring systems:

  • In IHC, use established scoring methods like H-score or Allred score.

  • For gastric cancer studies, researchers have successfully categorized NTR1 staining as negative, positive, or strongly positive to establish correlations with clinicopathological parameters .

• Internal controls:

  • Include calibration standards in Western blots.

  • Use housekeeping proteins for normalization.

  • Incorporate positive control tissues with known NTR1 expression levels.

• Digital image analysis:

  • Employ automated image analysis software for objective quantification.

  • Set consistent thresholds for positive staining across samples.

  • Consider both intensity and percentage of positive cells in analysis.

• Statistical considerations:

  • Account for tumor heterogeneity by analyzing multiple regions.

  • Use appropriate statistical tests for correlative studies.

  • Consider multivariate analysis to control for confounding factors.

How can NTR1 antibodies be utilized in targeted cancer therapies?

NTR1 antibodies offer several therapeutic applications:

• Antibody-drug conjugates (ADCs):

  • NTR1-targeted ADCs could deliver cytotoxic payloads specifically to cancer cells expressing high levels of the receptor.

  • Particularly promising for cancers with established NTR1 overexpression like gastric, breast, and colon cancers .

• Immunomodulatory approaches:

  • Bispecific antibodies linking NTR1 recognition with immune cell recruitment.

  • CAR-T cell designs incorporating anti-NTR1 targeting domains.

• Theranostic applications:

  • Dual-purpose NTR1 antibodies conjugated to both imaging agents and therapeutic payloads.

  • Enables real-time monitoring of therapeutic delivery and response.

• Combination therapies:

  • NTR1 antagonism combined with standard chemotherapies to prevent pro-survival signaling.

  • Targeting both NTR1 and β-catenin pathways to address multiple oncogenic mechanisms .

Research indicates NTR1 may be particularly valuable as a therapeutic target in gastric cancer, where its expression correlates with aggressive disease features and poor prognosis .

What emerging technologies can enhance NTR1 antibody specificity and sensitivity?

Advanced approaches to improve NTR1 antibody performance include:

• Recombinant antibody engineering:

  • Single-chain variable fragments (scFvs) targeting specific NTR1 epitopes.

  • Humanized antibodies for reduced immunogenicity in therapeutic applications.

  • Affinity maturation to enhance binding specificity and sensitivity.

• Novel detection systems:

  • Proximity ligation assays to visualize NTR1 interactions with signaling partners.

  • Super-resolution microscopy for nanoscale localization of NTR1 in membrane microdomains.

  • Multiplexed imaging to simultaneously detect NTR1 and multiple signaling proteins.

• Alternative targeting strategies:

  • Nanobodies against NTR1 for improved tissue penetration.

  • Aptamer-based detection systems as non-protein alternatives.

  • Cyclic peptides designed to bind specific NTR1 conformations.

These technological advances promise to overcome current limitations in NTR1 detection and therapeutic targeting.

How are NTR1 antibodies being used in combination with other biomarkers?

Integration of NTR1 with complementary biomarkers enhances diagnostic and prognostic value:

• Multi-marker panels:

  • Combining NTR1 with established cancer biomarkers improves sensitivity and specificity.

  • In gastric cancer, NTR1 assessment alongside β-catenin provides enhanced prognostic information .

• Spatial profiling:

  • Multiplex immunofluorescence incorporating NTR1 antibodies with markers of cancer stem cells, proliferation, and immune infiltration.

  • Digital spatial profiling to map NTR1 expression within the tumor microenvironment.

• Liquid biopsy integration:

  • Correlation of tissue NTR1 expression with circulating tumor cell characteristics.

  • Development of exosomal NTR1 detection methods for minimally invasive monitoring.

• Predictive biomarker applications:

  • Evaluating NTR1 expression as a predictor of response to specific therapeutic regimens.

  • Potential to guide patient selection for NTR1-targeted therapies.

Research has demonstrated that NTR1 expression provides valuable prognostic information complementary to traditional staging methods in gastric cancer .

What are the latest findings on NTR1 signaling pathways in disease progression?

Recent research has revealed complex roles for NTR1 signaling in cancer biology:

• Cross-talk with oncogenic pathways:

  • NTR1 activation influences β-catenin signaling, potentially promoting epithelial-mesenchymal transition .

  • Interactions with EGFR, MAPK, and PI3K/Akt pathways amplify pro-survival and proliferative signals.

• Microenvironmental influences:

  • NTR1 signaling may modulate tumor-stromal interactions and extracellular matrix remodeling.

  • Potential role in promoting angiogenesis through indirect mechanisms.

• Cell-type specific effects:

  • Differential NTR1 signaling outcomes in various cellular contexts.

  • In the nervous system, NTR1 is expressed in cholinergic neurons , while in cancer, it promotes cell proliferation and invasion .

• Therapeutic resistance mechanisms:

  • Upregulation of NTR1 has been observed in hormone-resistant prostate cancer models .

  • NTR1 signaling may contribute to chemoresistance through anti-apoptotic mechanisms.

Understanding these complex signaling networks will inform more effective targeting strategies and combination approaches for NTR1-expressing cancers.